The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression

被引:194
作者
Burnstock, Geoffrey [1 ,2 ,3 ]
Knight, Gillian E. [1 ]
机构
[1] UCL, Sch Med, Auton Neurosci Ctr, Rowland Hill St, London NW3 2PF, England
[2] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia
[3] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia
关键词
Pain; Infection; Cancer; CNS disorders; Cardiovascular; Airways; Diabetes; Kidney; Bladder; Liver; Gut; Immune cells; BRILLIANT BLUE G; TYPE-2; DIABETIC-RATS; P2X(7) RECEPTOR; PURINERGIC RECEPTORS; EXTRACELLULAR ATP; MOUSE MODEL; NLRP3; INFLAMMASOME; IN-VIVO; CELL INVASION; ANIMAL-MODEL;
D O I
10.1007/s11302-017-9593-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Seven P2X ion channel nucleotide receptor subtypes have been cloned and characterised. P2X7 receptors (P2X7R) are unusual in that there are extra amino acids in the intracellular C terminus. Low concentrations of ATP open cation channels sometimes leading to cell proliferation, whereas high concentrations of ATP open large pores that release inflammatory cytokines and can lead to apoptotic cell death. Since many diseases involve inflammation and immune responses, and the P2X7R regulates inflammation, there has been recent interest in the pathophysiological roles of P2X7R and the potential of P2X7R antagonists to treat a variety of diseases. These include neurodegenerative diseases, psychiatric disorders, epilepsy and a number of diseases of peripheral organs, including the cardiovascular, airways, kidney, liver, bladder, skin and musculoskeletal. The potential of P2X7R drugs to treat tumour progression is discussed.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 50 条
  • [31] The role of P2X7 in pain and inflammation
    Hughes, Jane P.
    Hatcher, Jonathan P.
    Chessell, Iain P.
    PURINERGIC SIGNALLING, 2007, 3 (1-2) : 163 - 169
  • [32] The role of P2X7 in pain and inflammation
    Jane P Hughes
    Jonathan P Hatcher
    Iain P Chessell
    Purinergic Signalling, 2007, 3 : 163 - 169
  • [33] P2X7 Receptor Signaling Pathway as a Therapeutic Target for Neurodegenerative Diseases
    Takenouchi, Takato
    Sekiyama, Kazunari
    Sekigawa, Akio
    Fujita, Masayo
    Waragai, Masaaki
    Sugama, Shuei
    Iwamaru, Yoshifumi
    Kitani, Hiroshi
    Hashimoto, Makoto
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2010, 58 (02) : 91 - 96
  • [34] Purinergic P2X7 Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis
    Mckenzie, Andre D. J.
    Garrett, Taylor R.
    Werry, Eryn L.
    Kassiou, Michael
    ACS CHEMICAL NEUROSCIENCE, 2022, 13 (10): : 1479 - 1490
  • [35] The P2X7 purinergic receptor: An emerging therapeutic target in cardiovascular diseases
    Chen, Zhe
    He, Lu
    Li, Lanfang
    Chen, Linxi
    CLINICA CHIMICA ACTA, 2018, 479 : 196 - 207
  • [36] Targeting P2X4 and P2X7 receptors in multiple sclerosis
    Domercq, Maria
    Matute, C.
    CURRENT OPINION IN PHARMACOLOGY, 2019, 47 : 119 - 125
  • [37] P2X7 receptors in cerebral ischemia
    Bai, Hui-Yu
    Li, Ai-Ping
    NEUROSCIENCE BULLETIN, 2013, 29 (03) : 390 - 398
  • [38] The role of P2X7 receptor in infection and metabolism: Based on inflammation and immunity
    Cai, Xiaoyu
    Yao, Yao
    Teng, Fei
    Li, Yangling
    Wu, Linwen
    Yan, Wei
    Lin, Nengming
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101
  • [39] Human melanomas express functional P2X7 receptors
    White, N
    Butler, PEM
    Burnstock, G
    CELL AND TISSUE RESEARCH, 2005, 321 (03) : 411 - 418
  • [40] Human melanomas express functional P2X7 receptors
    Nicholas White
    Peter E. M. Butler
    Geoffrey Burnstock
    Cell and Tissue Research, 2005, 321 : 411 - 418